The formula is indicated for the temporary relief of symptoms associated with hay fever, other respiratory allergies, and the common cold. This medication is commonly used to help manage acute symptoms across conditions characterized by periods of heightened symptoms, such as fever, body aches, nasal congestion, runny nose, and sneezing.

Management of Systemic Discomfort and Fever

This combination medicine is commonly used to help with symptoms related to systemic imbalance, specifically addressing body aches, muscle pains, and headache. The key therapeutic benefit is supporting the easing of overall symptom burden and contributing to fever control, which provides relevant symptomatic support during periods of heightened symptoms.

Addressing Nasal and Sinus Symptoms

The medication is applied in addressing clinical contexts where symptoms are driven by acute nasal and sinus congestion, resulting in a stuffy nose and feelings of sinus pressure. This function assists in providing supportive relief that helps ease nasal breathing and may assist with maintaining functional stability by managing physical nasal discomfort. This also includes the control of irritative manifestations like a runny nose and sneezing, which contributes to improved comfort.

Quick Fact: Targeted Symptom Management
Systemic Discomfort (Aches & Fever)
Nasal Congestion (Stuffy & Blocked Nose)
Irritative States (Sneezing & Rhinorrhea)

Regulatory References

1. National Library of Medicine (NIH) DailyMed overview

Eligibility for Coldact Flu Plus

Official regulatory documents define specific populations who are eligible for Coldact Flu Plus and groups for whom use is restricted or strictly prohibited. The medicine is primarily intended for use by adults and adolescents (generally 12 years and over, depending on regional guidelines) for the symptomatic relief of cold and flu.

---

Age-Related Eligibility Rules

Age Group	Regulatory Classification
Children	Use is contraindicated in children, with some authorities prohibiting use for those under 12 years or under 4 years [CDSCO].
Neonates/Infants	Contraindicated in newborn and premature infants.
Elderly	Use requires caution due to increased susceptibility to neurological anticholinergic effects.

---

Absolute Contraindications (Must Not Use)

Use is strictly contraindicated for patients with: Severe hypertension or severe cardiovascular disease; Severe hepatic or renal insufficiency; Closed-angle glaucoma; Phaeochromocytoma; and those currently taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping MAOI therapy. Contraindication also applies to conditions causing obstruction, such as a stenosing peptic ulcer.

Pregnancy and Lactation Status

The medicine is officially classified as not recommended for women who are pregnant or breastfeeding.

Interactions with other medicines and products

Official government regulatory documents classify several medicinal products and substances as having documented interactions with the components of Coldact Flu Plus (Paracetamol, Phenylephrine, and Chlorpheniramine).

Contraindicated Combinations and Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited. This combination, including use within 14 days of stopping an MAOI, is contraindicated due to the risk of hypertensive crisis from the Phenylephrine component. The product is also restricted from use alongside any other medicine containing Paracetamol or Acetaminophen to prevent potential severe liver toxicity.

Pharmacodynamic Interaction Patterns

This medicine has officially documented additive CNS depressant effects when used with substances classified as Central Nervous System (CNS) Depressants. These include alcohol, opioid analgesics, and hypnotics, which enhance the sedative capacity of the Chlorpheniramine component. Furthermore, the pressor effect of Phenylephrine is augmented by Oxytocic Drugs and certain Tricyclic Antidepressants, increasing the risk of cardiovascular events.

Metabolic and Exposure-Altering Interactions

Interactions involving the metabolism of the Paracetamol component are documented with substances that induce or regulate hepatic cytochrome enzyme CYP2E1, which may increase hepatotoxic potential. For individuals taking oral anticoagulants, such as Warfarin, chronic use of Paracetamol has been shown to cause an increase in the International Normalized Ratio (INR).

Population-specific interaction notes indicate that the drug is contraindicated in patients with Severe Hepatic Impairment or Active Liver Disease.

Coldact Flu Plus is a fixed-dose combination containing two pharmacologically active agents, a decongestant, and an antihistamine, that modulate distinct physiological pathways. The decongestant component, Phenylpropanolamine (PPA), functions as a sympathomimetic amine. PPA binds to and activates alpha-adrenergic receptors located primarily on the smooth muscles surrounding arterioles in the nasal mucosa and other localized microvasculature. This interaction initiates an intracellular cascade involving Gq protein signaling, leading to increased levels of inositol trisphosphate (IP3) and diacylglycerol (DAG), which ultimately trigger Ca^2+ release. The resulting increase in intracellular calcium concentration causes vasoconstriction of these blood vessels, leading to a reduction in local tissue edema and vascular engorgement.

The antihistamine component, Chlorphenamine Maleate, acts as a competitive antagonist at peripheral H1 histamine receptors. By binding to the H1 receptor, Chlorphenamine prevents endogenous histamine from initiating the downstream signaling pathway typically associated with histamine release. This competitive blockade inhibits histamine-mediated increases in capillary permeability and the resulting plasma exudation into tissues. The combined action provides complementary modulation of local physiological processes through two separate receptor systems.

General Principles of Administration

Coldact Flu Plus is an oral medication containing Acetaminophen, Phenylephrine, and Chlorpheniramine, and its administration is strictly defined by regulatory guidance, focusing on dose, frequency, and duration of use. The medication is intended solely for the oral route as a solid dosage form, such as a tablet or capsule. The proper procedural constraint is that the tablet or caplet must be swallowed whole with water and must not be crushed, chewed, or dissolved. The timing of intake is flexible and may occur either with or without food.

---

Dosing and Frequency Patterns

The standard dosing regimen is generally 1 or 2 tablets per dose for adults and adolescents aged 12 years and over. A key instruction is the minimum dosing interval, which specifies that the next dose should only be taken after an interval of 4 to 6 hours has elapsed. The official instructions impose a strict maximum daily dose, requiring that patients must not exceed 6 doses or tablets in any 24-hour period for the commonly cited 500 mg Acetaminophen strength. This overall limit is critical and requires individuals to avoid taking Coldact Flu Plus concurrently with any other Acetaminophen-containing products.

---

Duration and Special Use Constraints

Regulatory documentation designates Coldact Flu Plus for short-term use, often specifying a maximum treatment duration of 3 to 7 days for acute symptoms, depending on regional guidance. The product's standard dosage is specifically intended for adults and children 12 years of age and over, and the use of this formulation in children under 12 years is not authorized by the standard label. If a dose is missed, individuals should resume the schedule at the next required interval, never doubling the dose to compensate.

Research evidence / Overview of studies for Coldact Flu Plus

---

Clinical Evidence for Symptomatic Relief of the Common Cold

Research has extensively explored the use of this combination medicine in studies focused on episodic symptom patterns associated with the common cold. The evidence base primarily relies on short-term Randomized Controlled Trials (RCTs) where the medicine was evaluated against an inactive substance (placebo). These studies were mainly conducted on adults presenting with multiple, acute symptoms.

In these trials, studies monitored various outcomes related to physical discomfort. Researchers commonly measured changes in the Total Symptom Score (TSS), which is a method used in research exploring how symptoms change over time by combining patient-reported scores for symptoms like headache, fever, muscle aches, and congestion. Findings describe short-term changes related to patient-reported outcomes describing perceived discomfort.

While research provides insight into short-term changes, long-term effects are not fully established. Additionally, evidence quality varies across studies, and some systematic reviews, which combine multiple trial results, scientific literature indicates that the measured change in specific individual symptoms may be small. Comparative evidence is lacking to show how this specific three-ingredient combination was evaluated versus formulas containing only one or two ingredients.

---

Research Findings for Flu-like Illness

The research structure for flu-like illness was evaluated in trials often framed within the common cold evidence base. The product was observed in short-term RCTs that focused on conditions characterized by fluctuating or episodic manifestations where symptoms include fever and systemic discomfort. The trials focused on adults presenting with periods of heightened symptom activity.

Research examined patterns observed in studies for the common cold, with evidence derived from settings with varying symptom burdens focusing on how symptoms evolved in the observed populations.

Research on Use in Specific Populations

The majority of the research, including the main RCTs, reflects results that apply only to the populations studied—adults under the age of 65.

Evidence for the use of this medicine in children remains limited. While post-marketing surveillance reports was observed in some studies involving children aged two to five years, data for certain groups remain insufficient.

Gaps in the Research and Areas of Uncertainty

The body of evidence, while providing context, also highlights specific areas where uncertainty is noted or where more research is needed. One key limitation is the lack of extensive research exploring the evaluation of the specific three-drug combination (analgesic, antihistamine, and decongestant).

Furthermore, data are still emerging regarding the evaluation of the oral Phenylephrine component. Research is ongoing to provide clarity on its specific contribution to nasal congestion measures.

Key Studies & References

1. Study Details | Efficacy and Safety of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Common Cold and Flu Syndrome (Trial ID: NCT01389518)
2. Post-Marketing Surveillance Study to Substantiate the Efficacy and Safety for the Combination of Paracetamol, Phenylephrine, Chl... in Children of Age between 2 to 12 years

Common questions about Coldact Flu Plus (FAQ)

---

Q: How quickly does Coldact Flu Plus usually start working?

A: Official product information does not specify the exact time required for the initial onset of action. However, the standard dosing schedule typically indicates that a new dose may be taken after an interval of 4 to 6 hours, which provides a general framework for the expected duration of the effects.

---

Q: Can Coldact Flu Plus cause dizziness or drowsiness?

A: Yes, official documentation for the active ingredients includes reports of potential side effects such as drowsiness, sedation, or dizziness. These effects are often associated with the antihistamine component. Regulatory documents indicate that these potential effects should be considered before engaging in activities that require full attention.

---

Q: Is it true that Coldact Flu Plus contains both a pain reliever and a decongestant?

A: According to the official product description, Coldact Flu Plus contains three active ingredients. These include Acetaminophen, which is classified as a pain reliever (analgesic), and Phenylephrine, which acts as a nasal decongestant. The combination is formulated to address multiple acute cold and flu symptoms.

---

Q: Is Coldact Flu Plus suitable for use by older adults?

A: Regulatory guidance often advises caution regarding use in older adults, particularly those who have pre-existing conditions like liver or kidney impairment. This is because older individuals may have an increased susceptibility to certain side effects associated with the ingredients. The decision for use should be discussed with a healthcare professional.

---

Q: Can people with liver or kidney issues use Coldact Flu Plus?

A: Official documents generally state that this medicine is contraindicated, or advised against, for individuals with severe hepatic impairment or active liver disease. For those with less severe liver issues or any kidney issues, caution is warranted. The decision for use should be discussed with a healthcare professional.

---

Q: Why is Coldact Flu Plus often compared to other popular cold remedies?

A: Official research summaries note that there is a lack of extensive comparative evidence evaluating this specific three-ingredient formula versus remedies that contain only one or two ingredients. This absence of direct comparison in formal research may contribute to common public comparisons with other available cold medicines.

---

Q: What is the official definition of 'short-term use' for Coldact Flu Plus?

A: The official regulatory documentation designates this medicine for 'short-term use.' This often specifies a maximum treatment duration, typically ranging between 3 and 7 days, for the treatment of acute symptoms, depending on regional guidance.

---

Q: Is Coldact Flu Plus used for allergies or only for flu?

A: While primarily indicated for cold and flu symptoms, the product does contain Chlorpheniramine, which is an antihistamine. Antihistamines are commonly used to relieve certain allergy symptoms such as a runny nose and sneezing, and it addresses these similar symptoms during a cold.

---

Q: What are the most common things people report feeling after taking Coldact Flu Plus?

A: Commonly reported general effects in regulatory documents are usually associated with the active ingredients. These may include mild effects such as drowsiness, dizziness, dry mouth, nausea, or feelings of restlessness or nervousness.

---

Q: What types of medications should I check for potential interactions with Coldact Flu Plus?

A: The official product information describes interactions with several categories of medicine. These include Monoamine Oxidase Inhibitors (MAOIs), other Acetaminophen-containing products, CNS depressants (including alcohol), and certain antidepressants like tricyclics.

---

Q: Can Coldact Flu Plus affect your sleep?

A: Official documentation for the active ingredients lists trouble sleeping or nervousness as a potential side effect. Additionally, the antihistamine component (Chlorpheniramine) can cause drowsiness or sedation, which may impact sleep patterns.

---

Q: Does Coldact Flu Plus show up in drug screening tests?

A: Official guidance sometimes discusses how the decongestant component, Phenylephrine, is classified as a sympathomimetic amine. These substances do not typically cause a confirmed positive result for prohibited illegal substances on standard drug tests. Individuals should be aware of this classification when undergoing testing.

---

Q: What is the general age restriction for using Coldact Flu Plus?

A: The product's standard adult formulation is specifically intended for adults and children 12 years of age and over. Use of this specific formulation is not authorized by the standard regulatory label for children under 12 years.

---

Q: Why does the packaging say to check with a doctor if you have certain health conditions?

A: Regulatory guidance includes warnings because the medicine is either contraindicated or requires caution for individuals with certain pre-existing health conditions. This is due to the risks associated with the active ingredients, such as those with high blood pressure, heart disease, severe liver disease, or glaucoma.

---

Q: What happens if someone accidentally takes more Coldact Flu Plus than recommended?

A: The official label contains strong warnings about the serious risks of exceeding the recommended dose. This concern is primarily due to the Acetaminophen component and the potential for severe liver toxicity. Official guidance emphasizes the importance of seeking immediate medical help if more than the recommended amount is taken.

---

Q: Is it normal for me to feel a little bit of nausea after taking Coldact Flu Plus?

A: Official documentation for combination cold medicines sometimes includes general gastrointestinal effects among the commonly reported side effects. This can include mild symptoms like nausea or stomach upset.

---

Q: Can Coldact Flu Plus be used if the main symptom is a headache?

A: Official sources state the medicine contains Acetaminophen, which is indicated to relieve pain, including headache. However, the medicine is a combination product designed to address multiple acute cold symptoms, not just isolated pain.

---

Q: What does the research say about the effectiveness of the ingredients in Coldact Flu Plus?

A: Studies have explored the use of this combination for episodic symptoms of the common cold. Research has described short-term changes related to patient-reported outcomes of discomfort. Official summaries also indicate that evidence quality varies across studies, and long-term effects have not been fully established.

---

Q: Is Coldact Flu Plus classified as a prescription or over-the-counter medicine?

A: Coldact Flu Plus is widely classified as an over-the-counter (OTC) medicine in most jurisdictions. This means that, based on its formulation and recommended use, it can be purchased without a prescription.

---

Q: Are there known food or drink restrictions when using Coldact Flu Plus?

A: Official documents explicitly state a restriction against using the medicine with alcohol. This is due to the potential for enhanced Central Nervous System (CNS) depressant effects and an increased risk of liver toxicity caused by the Acetaminophen component.

---

Q: Is Coldact Flu Plus suitable for people with a history of heart problems?

A: Official documents state that the use of this medicine is contraindicated or requires caution in individuals with certain heart problems or high blood pressure, due to the presence of the decongestant component, Phenylephrine.

---

Q: Why might a person feel restless or jittery after taking Coldact Flu Plus?

A: The decongestant component, Phenylephrine, is classified as a sympathomimetic amine. Side effects associated with this class of ingredients, such as restlessness, anxiety, or nervousness, are noted in the official regulatory documentation.

---

Q: Are there different formulas or strengths of Coldact Flu Plus available?

A: Official sources generally describe the original product as a solid oral dosage form, such as a tablet or capsule, at a specific strength. The availability of other formulas or strengths may vary depending on the country or region of sale.

---

Q: What are the general instructions for stopping the use of Coldact Flu Plus?

A: Official guidance designates the medicine for short-term use. Official documentation indicates that the medicine is not intended for chronic use, and its administration is limited to short-term periods. The product label notes that the period of use should not extend beyond a specified duration (e.g., 3-7 days).

---

Q: Is there any specific population that is strictly advised against using Coldact Flu Plus?

A: Specific populations strictly advised against use, or contraindicated, include individuals with severe hepatic impairment, those taking Monoamine Oxidase Inhibitors (MAOIs), and children under 12 years of age for the standard adult formulation.

---

Q: How should Coldact Flu Plus be stored according to official recommendations?

A: Official recommendations state that the product should be stored in its original container, tightly closed, at a specified temperature (often at or below 30°C). It should always be kept out of the sight and reach of children.

---

Q: Is Coldact Flu Plus a non-steroidal anti-inflammatory drug (NSAID)?

A: No, the pain-relieving component of this medicine is Acetaminophen, which is classified as an analgesic and antipyretic (fever-reducer). This is a different class of medicine than a non-steroidal anti-inflammatory drug (NSAID), such as ibuprofen.

---

Q: Can I take Coldact Flu Plus if I have asthma?

A: Caution is often advised in official documents for people with respiratory conditions like asthma. Due to the potential effects of the decongestant and antihistamine components, official documents note that consultation with a healthcare professional is advised.

---

Q: Are there official reports of serious side effects related to Coldact Flu Plus?

A: Yes, regulatory documents list a range of potential serious adverse effects in their Warnings sections. These include the risks of severe liver damage (from the Acetaminophen component) and rare but serious skin reactions. These are described in the Warnings section of the official label.

---

Q: Does Coldact Flu Plus cause dry mouth?

A: Yes, dry mouth is a common side effect associated with the antihistamine component (Chlorpheniramine) and is reported in the official regulatory documentation for the medicine.

---

Q: Is Coldact Flu Plus available in a liquid or chewable form?

A: Official product information typically describes the standard formulation as a solid oral dosage form (tablet or capsule) to be swallowed whole. The availability of other forms, such as liquid or chewable, may vary depending on the specific authorized product in a region.

Storage and Disposal Information

This section outlines the official regulatory requirements for storing and disposing of Coldact Flu Plus, strictly based on authorized government drug labeling.

Requirement Type	Official Statement
Temperature	Store below 30 C.
Child Safety	Keep out of the sight and reach of children.
Disposal Rule	Do not dispose of medicine via wastewater or household waste.

Official labeling mandates that the product must be stored at a temperature not exceeding 30 C to maintain its stability and quality. The regulatory guidelines emphasize child protection, requiring the medicine to be stored in a location inaccessible to children. Furthermore, disposal instructions strictly prohibit flushing the product or placing it in the regular trash, stipulating that unused or expired medicines must be discarded according to local regulatory and environmental waste protocols.